240 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
10450960	3	Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum.	Schering-Plough Research Institute
26367391	6	Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.	Heidelberg University
26233795	21	Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids.	Heidelberg University
25768704	4	Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.	Shandong University
25456385	36	Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.	TBA
25438757	11	Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.	China Pharmaceutical University
25305334	32	A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.	University of Kwazulu-Natal
25221663	41	C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.	Heidelberg University
25155387	11	Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.	Idenix Pharmaceuticals
23727045	1	Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.	Wichita State University
14505664	17	Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors.	Eli Lilly
19402666	2	Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.	Abbott Laboratories
17113777	1	Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.	Uppsala University
17034123	1	Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.	The Pennsylvania State University
16908138	32	Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.	Boehringer Ingelheim Pharmaceuticals
16621533	4	Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease.	Sunway University College
16078825	8	Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.	Schering-Plough Research Institute
15633995	66	Control of hepatitis C: a medicinal chemistry perspective.	University of Wollongong
15546725	3	Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.	Peking University
11985465	22	Solid-phase library synthesis, screening, and selection of tight-binding reduced peptide bond inhibitors of a recombinant Leishmania mexicana cysteine protease B.	Carlsberg Laboratory
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
1527792	55	Specific inhibition of HIV-1 protease by boronated porphyrins.	University of California
1875332	33	HIV protease: a novel chemotherapeutic target for AIDS.	Merck Sharp and Dohme Research Laboratories
11206459	29	Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.	Uppsala University
11055336	2	NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.	Boehringer Ingelheim Pharmaceuticals
11055335	27	Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.	Boehringer Ingelheim Pharmaceuticals
9873421	30	Peptide-based inhibitors of the hepatitis C virus serine protease.	Boehringer Ingelheim (Canada)
	37	Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties	TBA
19703770	32	Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.	Sanford-Burnham Medical Research Institute
19700319	19	Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids.	Roche Palo Alto
19709881	13	Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.	Roche Palo Alto
	24	Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture	TBA
	5	Inhibition of human rhinovirus 3C protease by homophthalimides	TBA
	7	Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease	TBA
	4	Novel, selective mechanism-based inhibitors of the herpes proteases	TBA
	8	Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease	TBA
19464175	5	Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.	Institute of Science and Technology
18479921	1	Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.	Abbott Laboratories
16759084	12	Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.	Peking University
16730985	13	P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.	Schering-Plough Research Institute
16722622	24	Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.	Wyeth Research
16451069	55	SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.	Amgen
16451063	139	3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.	Glaxosmithkline
16274990	21	Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.	Wyeth Research
16246563	30	Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.	Novartis Institute For Tropical Diseases
16246553	12	Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.	Novartis Institute For Tropical Diseases
16190750	7	Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.	Schering-Plough Research Institute
16112859	6	Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.	Schering-Plough Research Institute
15982872	24	Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.	Pharmaceutical Research Institute
15801859	40	Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors.	Imim/Universitat Pompeu Fabra
15588076	6	The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.	Mrl Rome
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15261297	18	P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.	Eli Lilly
15203137	6	Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase.	University of Alberta
15115392	52	Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.	Schering-Plough Research Institute
15080998	21	Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease.	Irbm, Mrl Rome
15006379	44	Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.	Vertex Pharmaceuticals
14741292	18	Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.	Shire Biochem
14741291	19	Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.	Shire Biochem
14695826	13	NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.	Boehringer Ingelheim (Canada)
14684339	33	Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
14684338	44	P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.	Eli Lilly
14684337	31	Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor.	Eli Lilly
14684311	77	Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.	Boehringer Ingelheim (Canada)
14640544	7	Application of the lambda-dynamics method to evaluate the relative binding free energies of inhibitors to HCV protease.	Schering-Plough Research Institute
14611859	3	Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease.	Schering-Plough Research Institute
14521407	87	Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.	Glaxosmithkline
14505653	9	Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties.	Wyeth Research
12951122	20	Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase.	Shire Biochem
12873506	8	Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures.	Mrl Rome
12643933	27	Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.	Bristol-Myers Squibb
12643923	22	Glycine alpha-ketoamides as HCV NS3 protease inhibitors.	Pharmaceutical Research Institute
12617891	37	Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
12540231	39	Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.	Mrl Rome
12372533	69	P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.	Bristol-Myers Squibb Pharmaceutical Research Institute
12067545	22	Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.	Glaxosmithkline
11985469	22	Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.	Pfizer
11931615	46	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.	Agouron Pharmaceuticals
11909704	43	Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.	Schering-Plough Research Institute
11844706	30	Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.	Irbm, Mrl Rome
11844690	8	Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.	Roche Discovery Welwyn
11754575	51	Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.	Glaxosmithkline
11720861	24	Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.	Merck Research Laboratories
11527730	27	Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.	Bristol-Myers Squibb Pharmaceutical Research Institute
32605372	92	A New Class of Dengue and West Nile Virus Protease Inhibitors with Submicromolar Activity in Reporter Gene DENV-2 Protease and Viral Replication Assays.	Heidelberg University
31980339	27	Inhibitors of the Zika virus protease NS2B-NS3.	Australian National University
11206478	18	Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.	Institute of Molecular and Cell Biology
32292558	4	Catching a Moving Target: Comparative Modeling of Flaviviral NS2B-NS3 Reveals Small Molecule Zika Protease Inhibitors.	Freie Universit£T Berlin
11087570	14	Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template.	Glaxo Wellcome Research and Development
11055338	8	Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease.	Smithkline Beecham Pharmaceuticals
27520942	57	Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.	Idenix Sarl, An Msd
26771861	22	The Medicinal Chemistry of Dengue Virus.	Heidelberg University
10794684	34	Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.	Agouron Pharmaceuticals
10782670	11	Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.	Dupont Pharmaceuticals
10522707	16	2-chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus protease.	Glaxowellcome Medicines Research Centre
31128447	32	Recent update on anti-dengue drug discovery.	Queensland University of Technology
31176698	15	Backbone modifications in peptidic inhibitors of flaviviral proteases.	Heidelberg University
10197965	13	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.	Agouron Pharmaceuticals
10197964	32	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.	Agouron Pharmaceuticals
10091700	36	Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism.	Smithkline Beecham Pharmaceuticals
10091699	97	Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones.	Smithkline Beecham Pharmaceuticals
31804823	10	Peptide-?-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.	Heidelberg University
29400967	136	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.	Bristol-Myers Squibb
9873627	4	Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.	University of Michigan
31413794	2	Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.	Heidelberg University
31244113	27	Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.	Seoul National University
31549836	54	Drugs for the Treatment of Zika Virus Infection.	University of North Carolina At Chapel Hill
31351847	35	Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.	Federal University of Alagoas
31103899	15	Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors.	Heidelberg University
9667976	58	beta-Lactam derivatives as inhibitors of human cytomegalovirus protease.	Boehringer Ingelheim (Canada)
9667970	1	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.	Agouron Pharmaceuticals
9667969	21	Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.	Agouron Pharmaceuticals
31769670	32	Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases.	Johannes Gutenberg University Mainz
30783498	32	Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease.	Australian National University
9406601	109	Peptidomimetic inhibitors of the human cytomegalovirus protease.	Boehringer Ingelheim
30368131	46	Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.	Cnrs Umr7258
9171866	12	Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.	Merck Research Laboratories
8978838	24	Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.	Agouron Pharmaceuticals
29328649	4	Phenylthiomethyl Ketone-Based Fragments Show Selective and Irreversible Inhibition of Enteroviral 3C Proteases.	Freie Universit£T Berlin
27191615	63	2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors.	Gwangju Institute of Science and Technology (Gist)
23517538	15	Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.	Uppsala University
24900813	6	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.	Uppsala University
23672640	1	Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.	Array Biopharma
24900818	100	Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.	Merck Research Laboratories
8126707	18	Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.	University of California
23084906	42	Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.	Merck Research Laboratories
23062551	14	Development of anti-coxsackievirus agents targeting 3C protease.	Gwangju Institute of School of Life Sciences
24900473	21	Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.	Merck Research Laboratories
20947359	18	Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.	Academia Sinica
20673728	10	Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.	Uppsala University
20541424	12	Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.	Uppsala University
20108931	78	Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.	University of Basel
17938182	3	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.	Vertex Pharmaceuticals
17556358	4	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.	Vertex Pharmaceuticals
30064119	8	In silico fragment-based drug design with SEED.	University of Z£Rich
30365311	26	4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.	Nankai University
29137867	29	Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase.	Universit£
29866517	19	Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.	Korea Research Institute of Chemical Technology
30153009	56	Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.	Umr 7273 Cnrs
29477077	17	Pan-NS3 protease inhibitors of hepatitis C virus based on an R	Uppsala University
29454920	37	Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.	Chia Tai Tianqing Pharmaceutical Group
28835799	28	Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.	Wuxi Apptec (Shanghai)
29433930	14	Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.	Novartis Institutes For Biomedical Research
29653491	215	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).	Abbvie
29162454	43	The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.	Bristol-Myers Squibb
29801997	11	Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase.	Novartis Institute For Tropical Diseases
29779977	26	Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.	Emory University
25746232	16	Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.	University of Illinois At Chicago
26247308	20	Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors.	Birla Institute of Technology
25126694	21	Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication	University of Wisconsin-Milwaukee
23594083	7	Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance.	University of Massachusetts Medical School
23311976	16	Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors.	Umdnj-New Jersey Medical School
19839643	11	Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.	Uppsala University
19144641	8	Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.	National Yang-Ming University
21270126	3	Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.	Boehringer Ingelheim (Canada)
19877603	51	Identification and Biological Evaluation of a Series of 1H-Benzo[de]isoquinoline-1,3(2H)-diones as Hepatitis C Virus NS5B Polymerase Inhibitors.	Irbm, Mrl Rome
19054673	66	5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.	Anadys Pharmaceuticals
18554907	35	Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.	Anadys Pharmaceuticals
18662878	12	4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.	Anadys Pharmaceuticals
18722768	10	Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.	Anadys Pharmaceuticals
18242088	26	Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.	Anadys Pharmaceuticals
18487044	16	Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.	Anadys Pharmaceuticals
19419203	12	Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.	National Taiwan University
19022670	8	Potent inhibitors of HCV-NS3 protease derived from boronic acids.	Schering-Plough Research Institute
19154150	19	Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.	Schering-Plough Research Institute
19168351	18	Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.	Schering-Plough Research Institute
19102654	32	Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.	Schering-Plough Research Institute
17444623	29	Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.	Schering-Plough Research Institute
16451065	31	Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.	Schering-Plough Research Institute
17004721	49	Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor	Schering-Plough Research Institute
16387495	8	Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.	Schering-Plough Research Institute
16112862	9	Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.	Schering-Plough Research Institute
16413182	18	Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.	Schering-Plough Research Institute
15501035	12	Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.	Schering-Plough Research Institute
16087332	33	Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.	Schering-Plough Research Institute
16420042	9	Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.	Schering-Plough Research Institute
16640336	16	Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.	Schering-Plough Research Institute